NCT06388967View on ClinicalTrials.gov

Pancreatic Cancer Detection Consortium

RecruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

November 21, 2025

Study Completion Date

November 21, 2025

Conditions
Pancreatic CancerPancreatic CarcinomaPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPancreatic NeoplasmsPancreatic Cancer Stage IPancreatic Cancer StagePancreatic Cancer ResectablePancreatic Cancer Stage 0Pancreatic Cancer Stage IIPancreatic Cancer Stage IIIPancreatic Cancer, AdultPancreatic Cancer Non-resectable
Interventions
DIAGNOSTIC_TEST

PANcreatic cancer Exosome Early detectiON (PANXEON)

This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Trial Locations (11)

29732

RECRUITING

Piedmont Medical Center, Rock Hill

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

61637

RECRUITING

OSF HealthCare, Peoria

70121

RECRUITING

Ochsner Medical Center, Jefferson

85004

RECRUITING

Translational Genomics Research Institute, Phoenix

85258

RECRUITING

Honorhealth, Scottsdale

91016

RECRUITING

City of Hope Medical Center, Monrovia

92663

RECRUITING

Hoag Center, Newport Beach

07960

RECRUITING

Atlantic Health System, Morristown

Unknown

RECRUITING

Nagoya University, Nagoya

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors
lead

City of Hope Medical Center

OTHER